Order Now!

+66 (0)65 858 6005

Herceptin (trastuzumab)

What is Herceptin?

Herceptin (chemical name: trastuzumab) can be used to treat HER2-positive breast cancer that is either early-stage or advanced-stage/metastatic.

Herceptin is currently approved by the U.S. Food and Drug Administration:

  • to treat metastatic HER2-positive breast cancer to stop the cancer from growing
  • to treat earlier stages of HER2-positive breast cancer, either as part of a regimen with chemotherapy or alone after a chemotherapy regimen that includes an anthracycline, to reduce the risk of the breast cancer coming back (recurrence)
  • in combination with Perjeta (chemical name: pertuzumab) and Taxotere (chemical name: docetaxel) before surgery to treat HER2-positive, early-stage (the cancer must be larger than 2 cm or cancer must be in the lymph nodes), inflammatory, or locally advanced-stage breast cancer with a high risk of metastasizing or becoming fatal
  • in combination with Perjeta and chemotherapy after surgery to treat HER2-positive, early-stage breast cancer with a high risk of recurrence
WOOCS v.2.3.4.2
Share on facebook
Share on whatsapp
Share on twitter
Share on skype
Share on email
Share on pinterest

Description

What is Herceptin?

Herceptin (chemical name: trastuzumab) can be used to treat HER2-positive breast cancer that is either early-stage or advanced-stage/metastatic.

Herceptin is currently approved by the U.S. Food and Drug Administration:

  • to treat metastatic HER2-positive breast cancer to stop the cancer from growing
  • to treat earlier stages of HER2-positive breast cancer, either as part of a regimen with chemotherapy or alone after a chemotherapy regimen that includes an anthracycline, to reduce the risk of the breast cancer coming back (recurrence)
  • in combination with Perjeta (chemical name: pertuzumab) and Taxotere (chemical name: docetaxel) before surgery to treat HER2-positive, early-stage (the cancer must be larger than 2 cm or cancer must be in the lymph nodes), inflammatory, or locally advanced-stage breast cancer with a high risk of metastasizing or becoming fatal
  • in combination with Perjeta and chemotherapy after surgery to treat HER2-positive, early-stage breast cancer with a high risk of recurrence

For more information click here or here.

สำหรับภาษาไทย